Transcript Daily

iShares NASDAQ Biotechnology Index (IBB) Rating Increased to Buy at Vetr Inc. The Cerbat Gem iShares NASDAQ Biotechnology Index logo iShares NASDAQ Biotechnology Index (NASDAQ:IBB) was upgraded by equities research analysts at Vetr from a hold rating to a buy rating in a research report issued on Tuesday, April 18th. The brokerage ... SPC Financial Inc. Sells 2,240 Shares of iShares NASDAQ ...Transcript Daily iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Usca Ria LLCSports Perspectives Vetr Inc. Upgrades iShares NASDAQ Biotechnology Index (IBB) to BuyBBNS Chaffey Breeze -Markets Daily -Community Financial News all 38 news articles »

More here:
iShares NASDAQ Biotechnology Index (IBB) Rating Increased to Buy at Vetr Inc. - The Cerbat Gem

If you're interested in biotechnology as applied to the field of human medicine, our Biotechnology Programmay be just what you're looking for. The M.S. in Biotechnology is a 21 month curriculum that includes two semesters of coursework and a year of full time research in a Texas Tech University Health Sciences Center lab or an internship with an industry lab.

There is no shortcut to a quality education; our faculty are active investigators conducting internationally recognized research in their respective fields. Consequently, graduates of our program move on to the next phases in their careers with the confidence that can only come from the experience of working full time in a state-of-the-art biomedical research laboratory.

GSBS 5000 Interprofessional ExperienceGSBS 5471 Core I: MoleculesGSBS 5372 Core II: CellsGSBS 5373 Core III: GenesGSBS 5174 Core IV: Biomedical SeminarGBTC 5020 Laboratory Methods

Total Credit Hours: 12

GBTC 6101 Biotechnology SeminarGBTC 6301 Introduction to BiotechnologyGBTC 6202 Biomedical InformaticsGBTC 5337 Techniques in BiotechnologyGSBS 5101 Responsible Conduct of Research*Elective* Mandatory 3 hour elective

Total Credit Hours: 13

Starting in the summer session, students have the option of working in a TTUHSC lab or securing an internship position with a biotechnology-based company. The two coursework options are below:

GBTC 7000 Research

Total Credit Hours: 6

GBTC 7000 ResearchGBTC 5199 Biotechnology Lab ReportElective

Total Credit Hours: 10-13

GBTC 7000 ResearchGBTC 5299 Biotechnology Final ReportElective

Total Credit Hours: 11-14

GBTC 6001 Biotechnology Internship

Total Credit Hours: 6

GBTC 6001 Biotechnology InternshipGBTC 5298 Biotechnology Internship Report

Total Credit Hours: 11

GBTC 6001 Biotechnology InternshipGBTC 5299 Biotechnology Final ReportElective

Total Credit Hours: 11-14

GBTC 5210 The MicrobiomeGBTC 5340 The Biology of Cancer

Read more:
Biotechnology Program | Texas Tech University Health Sciences ...

1 - 15 of 6,999 jobs

Joseph Associates

Philadelphia, PA

Director level position with a prestigious, east coast R&D client of mine.They offer an opportunity to play a significant role in their organization by creating and building a team to evaluate their...

posted 9 hours ago

Global Personnel Search Inc

Columbus, OH

Analytical ScientistColumbus, OHPosition Description:This Ph.D. Analytical Scientist (R&D) position will be responsible for leading the project from feasibility phase to commercial launch. We are...

posted 1 day ago

Bio Partners Search Group, LLC

Northern, Nj, NJ

The Associate Director, Commercial Analytics is responsible for supporting Marketing/Sales and Managed Care Markets Management in the following key areas: physician targeting, segmentation, sample...

posted 1 day ago

KOB Solutions, Inc.

Paramus, NJ

My client is actively recruiting for a Director of Clinical Operations to develop the internal infrastructure of this growing firm and oversee clinical trials operations. The ideal candidate will...

posted 1 day ago

Gallin Associates

Norristown, PA

Job Profile:Manager to oversee major key manufacturing transfer programs for a world class medical device manufacturer. The position will be responsible for managing the transfer of manufacturing...

posted 1 day ago

Med Exec Intl / MEIRxRS

Los Angeles, CA

VP Clinical & Regulatory Affairs needed in Los Angeles, CAVP Clinical and Regulatory Affairsneeded to develop and implement clinical studies and molecular diagnostics validation strategy. The...

posted 1 day ago

CHLOETA

Boise, ID

CHLOETA is a dynamic incident management firm that conducts and plans operations nationwide for a variety of public and private sector clients. Incident Management Team (IMT) ReservistAs an IMT...

posted 1 day ago

Regency Search Group

South Bend, IN

Company BackgroundFor 30 years, this research laboratory has been manufacturing and distributing a variety of enzymes and cofactors used in basic coagulation research. They are known and trusted by

posted 1 day ago

Spark Therapeutics, Inc

Philadelphia, PA

Individual with strong pharmacology and toxicology experience in developing AAV-based therapies. The candidate will be responsible for the strategy and execution of pharmacology and toxicology...

posted 2 days ago

Stabilis Professional Services

Andover, MA

Stabilis Professional Services, Inc. is looking for aBioinformatics Software Developer for their client in Andover, MA.Responsibilities: Designs, codes, tests, corrects and documents moderately...

posted 2 days ago

Excelsior Recruiting Group

New York, NY

BENEFITSCompetitive base starting at 90k plus commissionExcellent Benefits packageCompany CarGreat Growth Opportunity!!!QUALIFICATIONS Minimum of 10 years of sales & project experience in packaging

posted 3 days ago

Spark Therapeutics, Inc

Philadelphia, PA

The Research Scientist is a member of the Liver Discovery Research functional group within the Discovery Research group under Translational Research. He/she will be responsible for: Design and...

posted 4 days ago

Continental Search and Outplacement, Inc.

Indianapolis, IN

Leading company in animal agriculture seeks experienced sales professional to grow their market share in Indiana, Ohio and northern Kentucky. Candidates can live anywhere within the region andwork...

posted 4 days ago

Philadelphia, PA

The Assay Development Associate - Vector Shedding/Bio Distribution will: With guidance and supervision from the group leader or supervisor, conduct clinical and preclinical sample analysis per SOPs...

posted 4 days ago

Spark Therapeutics, Inc

Philadelphia, PA

The Sr. Regulatory Operations Specialist contributes to daily operations activities for preparation of regulatory submissions to FDA, EMA, and other key health authorities. They also collaborate...

posted 5 days ago

The rest is here:
BioTech Jobs in the BioTechnology Pharmaceuticals Industry

A Little Vertex Goes a Long Way For Biotechnology - Barron's Barron's Healthcare stocks are the second-best performing, behind just the information technology sector year-to-date. Healthcare stocks have gained 8.3%, while the ... and more »

Continued here:
A Little Vertex Goes a Long Way For Biotechnology - Barron's - Barron's

Post Analyst

Stifel Nicolaus Reiterates "Buy" Rating for Puma Biotechnology Inc (PBYI) The Cerbat Gem Puma Biotechnology Inc logo Stifel Nicolaus reaffirmed their buy rating on shares of Puma Biotechnology Inc (NYSE:PBYI) in a report released on Wednesday, April 19th. They currently have a $88.00 target price on the biopharmaceutical company's stock. Puma Biotechnology (PBYI) Getting Somewhat Positive Press Coverage, Report ShowsTranscript Daily Puma Biotechnology (PBYI) Getting Somewhat Positive Press Coverage, AlphaOne ReportsMarkets Daily Puma Biotechnology, Inc. (PBYI) held by 19 SEC 13F Filers | Post ...Post Analyst Chaffey Breeze -Bibeypost.com -Sports Perspectives all 22 news articles »

Read more from the original source:
Stifel Nicolaus Reiterates "Buy" Rating for Puma Biotechnology Inc (PBYI) - The Cerbat Gem

Puma Biotechnology Inc (NASDAQ: PBYI) is having an overwhelmingly rough start to the trading session this morning, and for good reason. Early this morning, it was announced that a key member of the management team will be leaving the company. As a result, fear struck investors, leading to declines in the stock. Of course, our partners at Trade Ideas were the first to alert us to the declines in the stock. Currently (9:12), PBYI is trading at $32.00 per share after a loss of $4.55 per share or 12.45% thus far today.

As mentioned above, Puma Biotechnology is having an overwhelmingly rough day in the market today after investors learned that a key executive has made the decision to leave the company. Early this morning, it came to light that on April 28th, Robert Charnas, senior vice president of regulatory affairs and project management, notified the company that he will be resigning for health reasons.

Of course, this is overwhelmingly bad news. After all, PBYI isn't the source of the health issues that forced the resignation, but they are sure going to deal with the pain associated with a key member of the team leaving.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

Moving forward, the CNA Finance team will be keeping a close eye on PBYI. In particular, we're interested in following the company to see who takes on the position that Charnas will leave. Nonetheless, we'll continue to follow the story closely and bring the news to you as it breaks.

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Read the rest here:
Puma Biotechnology (PBYI) Stock: Falling Hard On Robert Charnas Resignation - CNA Finance (press release)

Technology and biotechnology stocks once again top our list of momentum charts to watch.

Achaogen Inc. AKAO, +7.49% had an important snapback session on Tuesday, gaining $2.12, or 9.7%, to $23.90 on over 2 million shares traded. The move came on news that venture capitalist Robert Duggan disclosed a 5.7% stake in the late-stage biopharmaceutical company. Volume was the strongest on an up-day all year, and the stock has now bounced off rising trendline support after a 10-day pullback from the top of the channel to the bottom. If the stock can get through resistance, which is now up around Tuesdays high at $24.46, it could challenge recent highs around $26.75-$27.75 on the way to the top of the channel at over $30.

Cara Therapeutics Inc. CARA, +6.08% had a nice follow-through on Tuesday, jumping 94 cents, or 5%, to $19.09, on 7.6 million shares traded. The biotech company reported positive results in a trial of a treatment for uremic pruritus, or UP. The stock reached $20.24 intraday, the highest its been since September 2015. It came down in the afternoon and didnt close great, but from the standpoint of the daily pattern as well technicals and volume, the stock looks strong. It has climbed nicely off rising trendline support toward mid-channel in the past two weeks. The stock needs to hold lateral support at around $17.50. A move through Tuesdays high could lead to $23 short-term and $27 intermediate-term.

Kopin Corp. KOPN, -0.37% maker of wearable technologies and display products, had nice action on Tuesday, especially in the afternoon when it ran from about $3.90 to $4.19, backing off a little at the close. Net on the day, it gained 8 cents, or 2%, to $4.11 on strong volume of 643,000 shares. Volume has been strong in general in the past few weeks, indicating possible accumulation, and Tuesday saw the stock edge above its breakout point at around $4.09. Watch for $4.75 and then $5-$5.25 as targets.

Nektar Therapeutics NKTR, +1.13% had a breakout session on Tuesday, up 55 cents, or 2%, to $23.93 on 1.7 million shares. The company announced on Monday it has begun dosing in a Phase 1 study of its new biologic therapy to treat auto-immune diseases and inflammatory disorders. The move broke the stock out of a week-long consolidation zone that followed its nearly 50% gap up on March 20. The move came on only average volume. Nonetheless, watch for a run at $26 short-term.

Western Digital Corp. WDC, +1.66% is on the move. Stock in the data-storage company has been up five days in a row since its March 21 close at $73.22. Investors appear to have been encouraged by Micron Technologys MU, -0.66% strong quarterly forecast late last week, and optimism about memory and storage chip demand. On Tuesday, WDC gained $1.99, or 2.5%, to $80.56, on nearly 4 million shares traded. The stock is right at a lateral resistance level, and a pop through there could get it to $86-$87 and then the channel top near $95.

See Harrys video chart analysis on these stocks.

Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis, and live chart presentations.

Visit link:
Opinion: Harry Boxer's five technology and biotechnology stocks to watch - MarketWatch

The Cerbat Gem

Orbis Allan Gray Ltd Holds Stake in Puma Biotechnology Inc (PBYI) The Cerbat Gem Orbis Allan Gray Ltd held its position in Puma Biotechnology Inc (NYSE:PBYI) during the fourth quarter, according to its most recent 13F filing with the SEC. Puma Biotechnology, Inc. (PBYI) in-depth technical analysis | Post ...Post Analyst all 3 news articles »

See the rest here:
Orbis Allan Gray Ltd Holds Stake in Puma Biotechnology Inc (PBYI) - The Cerbat Gem

With excellent mechanical and chemical stability, the Kromasil EternityXT materials offer first-rate separation power and loadability for purification from low to high pH. Kromasil EternityXT C8 and C18 materials can operate up to pH 12, making it possible to run basic compounds under extreme conditions to improve purification productivity and reduce costs. These products support discovery, development and production departmental goals in the purification of a low molecular weight pharmaceuticals, peptides and biotechnology products.

The exceptional structure of Kromasil EternityXT C18 and C8 materials makes it possible to regenerate the material in-column, carrying out cleaning in place (CIP) even at 1 M NaOH, if so required. While this high concentration NaOH treatment is a standard in bio chromatography and until now only conceivable with polymer resins, Kromasil EternityXT materials open up the spectrum of purification options as its C8 and C18 materials resist up to 1 M NaOH.

Read the rest here:
Purification of Pharmaceutical and Biotechnology Products with Kromasil EternityXT Stationary Phase - Labmate Online

KARACHI: Pakistani agro-scientist should expedite their research activities in agro-biotechnology in order to create significant impact in enhancing agriculture production in the country.

Talking to the Daily Times, agro-biotechnology experts and agriculturists on cotton, maize, corn and other crops said Pakistan should follow the developed world and developing nations like The Philippines and India who have already made significant economic progress by adopting the latest agri-technologies.

Though Pakistan has been conducting regulatory field trials and research on ground for biotech cotton and corn but there was the need to exploit more avenues introduced in the modern agro-base technologies in the world.

The concerned government departments and ministry should also allocate more funds in this sector in the upcoming annual budget, they opined.

"Cotton has remained a vital cash crop and country needs above 16 million bales every crop season, as cotton related textile sector feeds a large number of direct and indirect employment besides textile export stands number one on five prime exporting sectors", President of Sindh Agriculture Forum, Shakeel Ahmad said.

The positive impact of biotech crops around the world is evident in reducing pesticide usage, which is subsequently a positive for the environment, he added.

Cotton, corn and wheat would continue to be important crops for our economy and farmers therefore we must continuously apply better technologies.

Water availability for agriculture is going down and while this will require major decisions, biotechnology can help in growing crops, which utilise less water and fertilizers.

Ahmad said there was dire need of biotechnology induction especially in major crops, as textile sector bore around $15-$20 billion on imports annually.

Greater velocity in research activities will help in improving rural farm incomes and bring positive economic impact to people in the traditional corn and cotton belts as well the northern parts of the country, cotton expert and patron-in-chief Pakistan Cotton Ginners Association, Rana Abdul Sattar said.

Pakistan should focus on attaining sustainable higher yields and better water management to avert food shortages in the coming two decades.

An expert on Life Sciences, Punjab University described biotechnology benefits for farmers and outlined the achievements in attaining enhanced maize and corn yields by farmers.

Bacillus Thuringiensis (Bt) maize and corn provides excellent season-long protection against the target pests like corn borer and stalk borer.

Corn contains a natural occurring protein (Bt) that helps protect plants from specific lepidopteron insect pests. They said with a growing population it is imperative that Pakistan should focus on attaining sustainable higher yields and better water management to avert food shortages in the coming two decades.

We need to be more focused and take quick decisions. The 21st century has begun with a population of 6.2 billion and likely to increase to 9.2 billion by 2050.

Follow this link:
Scientists asked to expedite research in agro-biotechnology - Daily Times

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide

Go here to see the original:
Biotechnology Innovation Organization's Amicus Brief in Sandoz v. Amgen - JD Supra (press release)

NEW YORK, March 27, 2017 /PRNewswire/ -- Use this report to:- Analyze existing and future agricultural biotechnology products and technologies that will be commercially important. - Receive a qualitative and quantitative description of the agricultural biotechnology industry. - Highlight key market and industry trends, as well as quantify the main market segments. - Receive information on agricultural biotechnologies, market applications, industry structure and competitive dynamics.

Highlights- The global market for agricultural biotechnology reached $29.2 billion in 2016. This market should reach $32.1 billion in 2017 and $53.7 billion in 2022, with a compound annual growth rate (CAGR) of 10.8%. - Genomic-enabled products as a segment reached $24.1 billion in 2016, and should reach nearly $26.5 billion in 2017 and $43.7 billion in 2022, with a CAGR of 10.6%.

STUDY GOALS AND OBJECTIVES BCC Research's goal for this study is to determine the specific applications and forecast global market demand for agricultural biotechnology products over a five-year period from 2017 through 2022. The main objective is to characterize and quantify the agricultural biotechnology products market by product type, geography, and purpose. In addition, the report analyzes the industry structure, competitors, strategic alliances, and intellectual property landscape. A total of 70 companies in the industry are profiled.

Agricultural biotechnology markets analyzed in this report include biotechnology tools, genomics enabled products, and biologicals. Biotechnology tools include DNA sequencing, biochips, RNA interference, synthetic biology, and genome editing. Genomics enabled products include biotech seeds and synthetic biology-enabled products. Biologicals include biopesticides, biostimulants, and genetic biologicals.

A key objective of the report is to provide a comprehensive analysis of the agricultural biotechnology industry, with an emphasis on products and technologies that are commercially important in the 2017 to 2022 time-period. Market segments with rapid growth rates are highlighted, as well as those segments with large market potential. This analysis provides a quantitative basis and market context for companies to make strategic choices about participation in the agricultural industry.

The study will be particularly useful to those companies developing new genomics or proteomics technologies; discovering and development novel seed traits; doing plant breeding; interested in using novel biotechnologies in agriculture; or working inadvanced biotechnology fields like genome editing, synthetic biology, RNA interference, biochips, or DNA sequencing.

The study will also be useful to government agencies or institutions that are developing strategic initiatives for a country's agriculture policy and/or industry.

REASONS FOR DOING THE STUDY

Agriculture is a fundamental and strategic component for a country. As a result, agricultural technologies provide competitive geographic advantage and are highly desirable. Biotechnologies address the pressing industry need for higher crop yields. Agricultural biotechnology is a key and growing component of the global agriculture industry and is thus of interest to a wide audience.

This report seeks to provide a qualitative and quantitative description of the agricultural biotechnology industry so that emerging market opportunities can be identified and exploited by the reader.

The report does this by examining the main product applications and markets, helping companies to prioritize product opportunities and strategic opportunities. The report highlights key market and industry trends, as well as quantifying the main market segments. The reader is thus able to better understand industry structure and changes occurring in the industry.

Rapid changes in technology-intensive fields such as DNA sequencing, genome editing, and synthetic biology are driving new products and applications in agriculture. These developments create unique market opportunities. This report analyzes these trends and their impact on future markets for agricultural products.

Based on these market and technology dynamics, it is especially timely to examine the agricultural biotechnology industry.

INTENDED AUDIENCE

Read More

This study examines and analyzes existing and future agricultural biotechnology products and technologies that will be commercially important.

Markets are presented by product type, crop type, and geographical region. Important market segments covered include the main biotechnologies (DNA sequencing, biochips, RNA interference, synthetic biology tools, and genome editing tools) as well as synthetic biology-enabled chemicals and biofuels, biotech seeds, and biologicals.

In-depth coverage is provided for agricultural biotechnologies; growth driving forces; market applications; industry structure and competitive dynamics; companies and industry alliances; future market potential and product sales forecasts for the period 2017 through 2022. The report forecasts the future value of agricultural biotechnology products by product type and geography.

This report will be of particular interest to agriculture, chemicals, bio-energy, and biotechnology companies; as well as suppliers of genomics tools, synthetic biology, RNA interference, and DNA sequencing products. It will also be of interest to professionals within governments, think tanks, and regulatory agencies to understand the end uses of these technologies in agriculture.

SCOPE AND FORMAT

The study scope includes key agricultural biotechnology tools (i.e., next generation DNA sequencing, biochips, RNA interference, synthetic biology tools and genome editing tools); synthetic biology-enabled chemicals and biofuels; biotech seeds; and biologicals.

BCC analyzes these technologies and products to determine present and future market sizes, and forecasted growth from 2017 through 2022. The report also discusses industry strategic alliances, industry structures, competitive dynamics, patent status, and market driving forces.

BCC provides in-depth coverage of the agricultural biotechnology industry structure, including genomics technology providers (e.g., genome editing, NGS, microarray companies); major seed companies; biotech traits companies; synthetic biology tools companies; companies developing plant feedstocks; and agricultural biologicals companies. It provides an in-depth analysis of major industry acquisitions and alliances during 2015 and 2016.

70 agricultural and biotechnology companies are profiled in this report.

METHODOLOGY

BCC Research examined key users and producers in each of the enduser market segments and technology fields that will be commercially important during the next five years. Discussions with industry thought leaders, as well as secondary market research was performed.

Based on our analysis, we project the future applications of agricultural biotechnologies in the major enduser market segments and by technology type, and forecast sales revenues for 2017 through 2022.

INFORMATION SOURCES

BCC Research performed primary and secondary research for this report. Primary sources included key industry companies and leading research institutions. In addition, data were compiled from secondary sources, including company websites and industry, trade and government publications. Read the full report: http://www.reportlinker.com/p0958100-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/agricultural-biotechnology-emerging-technologies-and-global-markets-300429907.html

Continue reading here:
Agricultural Biotechnology: Emerging Technologies and Global ... - Yahoo Finance

By Nicolas Chahine, InvestorPlace Contributor|Mar 28, 2017, 11:13 am EDT

It would seem that the toxicity that the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) were suffering on Wall Street is waning. Until recently, the political headlines were a threat to all healthcare and biotech stock holders.The thesis that biotech stocks are untouchable, however, is no longer the dark cloud that it was.

So can I buy the IBB long from here with confidence? Not in my opinion. I think that trading the IBB should fit into a bullish macro scenario, which we may no longer have. Equity markets are near all-time highs with few catalysts that are not yet priced in. Traders quickly priced in the fiscal spending and legislative advantage that President Trump promised. This week we saw the first promise die, so the onus is now on the bulls to prove they can deliver the rest.

Click to EnlargeSo to say the least, the perfectly bullish scenario has some rebuilding to do. This creates an opportunity to take a short-term bearish bet on the IBB. I can do this without spending any out-of-pocket money.

Before you label me a bear, I am merely shorting the near-term price action and not the fundamentals of any components within the IBB. In fact, I will leverage their value to pay for my bet.

The Trade: Buy the IBB June $280/$275 debit put spread for $1.30. This is a bearish trade that could triple my money if IBB falls through my spread before mid-June. The cost of entry is my maximum potential loss. I usually like to hedge my bets, and in this case, I will sell downside risk against the value of the IBB. The trick is to find proven support zones.

The Bank: Sell the IBB Jan $200 put and collect $3 per contract. The current 30% price buffer gives this leg a 90% theoretical chance of success. As long as IBB stock stays above my January sold strike, any premium I recover from selling the June debit put spread would be pure profit. Having no out-of-pocket risk makes managing this trade relatively easy.

Fair warning: Selling puts is risky, so only do it if you are willing and able to own the IBB shares at the strike price.

Nicolas Chahine is the managing director of SellSpreads.com. Learn options as easy as 1-2-3 here. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him on Twitter at @racernicand stocktwits at@racernic.

Article printed from InvestorPlace Media, http://investorplace.com/2017/03/short-the-ishares-nasdaq-biotechnology-index-etf-ibb-etf/.

2017 InvestorPlace Media, LLC

Read the original post:
IShares Nasdaq Biotechnology Index: Short the Near-Term Action in ... - Investorplace.com

GlobalAgriculture Biotechnology Market,added byGlobalMarketers.biz in its huge repository, offers a brilliant, complete research study of themarket. The report comprises a thorough study of essential market dynamics, including growth drivers, restraints, and opportunities. It chiefly focuses on current and historical market scenarios. It understands market competition, segmentation, geographical expansion, regional growth, market size, and other factors. The Agriculture Biotechnology research study will surely benefit stakeholders, market players, investors, and other market participants. They will get a sound understanding of the global market and the industry.

Get Sample [emailprotected]::https://www.globalmarketers.biz/report/ life-science/global-agriculture-biotechnologymarket-research-report-2020-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/145010#request_sample

The key manufacturers in this market include:

ADAMA Agricultural SolutionsVilmorinBayerBiocentury TransgeneCertisDow AgroSciencesEurofinsEvogeneGlobal Bio-chem TechnologySyngentaKWS SaatMarina BiotechMonsanto

Importantly, the Agriculture Biotechnology market report covers critical aspects of the competitive landscape and future changes in market competition. Market statistics such as market share, revenue, production, consumption, gross margin, and price are accurately calculated. Additionally, the report has provided pricing analysis, industry chain analysis, product and application analysis, and other vital studies, giving a complete picture of the globalAgriculture Biotechnology market. The research is done by adopting a market method that contained both bottom-up and top-down approaches.

To know more about how the report uncovers exhaustive insights |Enquire Here:https://www.globalmarketers.biz/report/ life-science/global-agriculture-biotechnologymarket-research-report-2020-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/145010#inquiry_before_buying

Geographically, this report is segmented into several key regions, 2025(forecast), coveringNorth America, Europe, Asia Pacific, South America, and the Middle East and Africa.

Competition By The Company: Here, the competition in the worldwide Agriculture Biotechnology market is analyzed, by price, revenue, sales, and market share by company, market rate, competitive situations landscape, and latest trends, merger, expansion, acquisition, and market shares of top players.

Segmentation Overview:

Product Type Segmentation :

BiochipsDeoxy ribonucleic acid (DNS) sequencingGenome editing toolsRibonucleic acid interference (RNAI)Synthetic biology

Application Segmentation :

Transgenic crops marketSynthetic biology-enabled products market

What Market Factors Are Explained In The Report?

The Agriculture Biotechnology market is segmented according to type, application, and region. A complete explanation of the market accumulating methodology, the use of advancement, conclusions of the world market players has been given. The segmentation study identifies leading segments and explains key factors supporting their growth in the global Agriculture Biotechnology market. The report then sheds light on product positioning, customers perception of market competition, customer segmentation, consumer buying behavior, customer needs, and target customers.

Check Table of Contents of This Report @https://www.globalmarketers.biz/report/ life-science/global-agriculture-biotechnologymarket-research-report-2020-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/145010#table_of_contents

Key Questions Answered In The Market Report:-

-What are the key strategies used by players and service providers that are expected to impact the growth of the Agriculture Biotechnology market?

-What are the resources exist in respective regions that attract leading players in the market?

-What are the most recent advanced technologies approved by the market?

-How are the recent trends affecting growth in the global Agriculture Biotechnology market?

-What was the historical value and what will be the estimate value of the market?

Request For Discount On This Report @https://www.globalmarketers.biz/discount_inquiry/discount/145010

See more here:
Global Agriculture Biotechnology Market To Witness The Highest Growth Globally In Coming Years 2020-2026 - Latest Herald

Menlo Therapeutics Inc (MNLO) is near the top in its industry group according to InvestorsObserver. MNLO gets an overall rating of 58. That means it scores higher than 58 percent of stocks. Menlo Therapeutics Inc gets a 72 rank in the Biotechnology industry. Biotechnology is number 60 out of 148 industries.

Click Here to get the full Stock Score Report on Menlo Therapeutics Inc (MNLO) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Menlo Therapeutics Inc (MNLO) stock is trading at $6.10 as of 12:18 PM on Tuesday, Jan 14, a rise of $0.50, or 8.93% from the previous closing price of $5.60. The stock has traded between $5.50 and $6.44 so far today. Volume today is light. So far 132,809 shares have traded compared to average volume of 181,677 shares.

To see InvestorsObserver's Sentiment Score for Menlo Therapeutics Inc click here.

Read the rest here:
Is Menlo Therapeutics Inc (MNLO) Stock a Good Buy in Biotechnology - InvestorsObserver

DUBLIN, Jan. 31, 2019 /PRNewswire/ --

The "Marine Biotechnology - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Global Marine Biotechnology market accounted for $3.93 billion in 2017 and is expected to reach $8.74 billion by 2026 growing at a CAGR of 9.3% during the forecast period.

Some of the important factors driving the market growth are current applications of marine derived enzymes in cosmetics, use of micro algae and marine algae in bio-field products. However, Lower R&D investment in the field is hampering the growth of the market. Some of the key opportunities is the Marine biotechnological advancements has been resulted successful in diverse fields with increasing investments from venture capitalists.

Marine biotechnology is a pioneering field of in recent science and technology that customs various marine bio resources for a huge number of uses, including the production of food, fuel, often bioactive, compounds and possibly will contribute to prosperous communities, green growth and sustainable industries. Even though marine biotechnology is in an emerging stage, it has unexploited potential and accomplished capability growth prospect for future.

By applications, Marine Natural Products for Medicine segment is held significant growth during the forecast period due to rising investment by key players and other factors like healthy and dietary supplements because they are rich in amino acids, proteins, vitamins, and minerals etc. Since the marine environment is the mainly biologically and chemically diverse habitat on the planet, marine biotechnology has, in recent years delivered an increasing number of most important therapeutic products, industrial and environmental applications and analytical tools.

By geography, Europe is anticipated to be one of the leading regions contributing to the global market during the forecast period. With Europe getting better from the economic crisis, the region has been making stable investments in marine biotechnology and is also witnessing the appearance of several small and micro and medium sized enterprise that are making major assistance to the R&D and opening of novel marine-based products. In additionally, the European Union research policy supports a number of collaborative projects in marine biotechnology.

What our report offers:

Key Topics Covered:

1 Executive Summary

2 Preface 2.1 Abstract2.2 Stake Holders2.3 Research Scope2.4 Research Methodology2.5 Research Sources

3 Market Trend Analysis 3.1 Introduction3.2 Drivers3.3 Restraints3.4 Opportunities3.5 Threats3.6 Product Analysis3.7 Technology Analysis3.8 Application Analysis3.9 End User Analysis3.10 Emerging Markets3.11 Futuristic Market Scenario

4 Porters Five Force Analysis 4.1 Bargaining power of suppliers4.2 Bargaining power of buyers4.3 Threat of substitutes4.4 Threat of new entrants4.5 Competitive rivalry

5 Global Marine Biotechnology Market, By Source 5.1 Introduction5.2 Corals and Sponges5.3 Macro Algae5.4 Marine Fungi5.5 Marine Viruses5.6 Micro Algae

6 Global Marine Biotechnology Market, By Product 6.1 Introduction6.2 Biomaterials6.3 Bioactive Substances6.4 Other Products

7 Global Marine Biotechnology Market, By Type 7.1 Introduction7.2 Marine Animal Technolog7.3 Marine Plant Technology

8 Global Marine Biotechnology Market, By Technology 8.1 Introduction8.2 Enrichment, Isolation and Cultivation of Microorganisms8.3 Culture-Independent Techniques8.4 Large Scale Implementation

9 Global Marine Biotechnology Market, By Application 9.1 Introduction9.2 Marine Aquaculture9.3 Marine Natural Products For Medicine9.4 Marine Nutraceuticals9.5 Marine Biomaterials9.6 Marine Bioenergy9.7 Marine Bioremediation9.8 Food & Feed9.9 Energy and Environment Management Products9.10 Fine Chemical9.11 Environment

10 Global Marine Biotechnology Market, By End User 10.1 Introduction10.2 Healthcare/Biotechnology10.3 Consumers Products10.4 Public Services & Infrastructure10.5 Industrial Products10.6 Pharmaceuticals10.7 Supplements10.8 Cosmetics

11 Global Marine Biotechnology Market, By Geography 11.1 Introduction11.2 North America11.3 Europe11.4 Asia Pacific11.5 South America11.6 Middle East & Africa

12 Key Developments 12.1 Agreements, Partnerships, Collaborations and Joint Ventures12.2 Acquisitions & Mergers12.3 New Product Launch12.4 Expansions12.5 Other Key Strategies

13 Company Profiling

For more information about this report visit https://www.researchandmarkets.com/research/jsv93b/global_marine?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original here:
Global Marine Biotechnology Market Report 2018: Drivers ...

Searching for wide presentation to the Healthcare Biotech portion of the value showcase? You ought to consider the Invesco Dynamic Biotechnology and Genome ETF (PBE), a latently overseen trade exchanged reserve propelled on 06/23/2005.

Inactively oversaw ETFs are getting progressively famous with institutional just as retail financial specialists because of their ease, straightforwardness, adaptability, and duty effectiveness. They are astounding vehicles for long haul financial specialists.

Area ETFs additionally give speculators access to a general gathering of organizations, specifically areas that offer an okay and broadened introduction. Human services Biotech is one of the 16 expansive Zacks areas inside the Zacks Industry arrangement. It is as of now positioned 2, setting it in the top 13%.

The store is supported by Invesco. It has amassed resources over $227.92 M, making it one of the normal measured ETFs endeavoring to coordinate the presentation of the Healthcare Biotech section of the value showcase. PBE looks to coordinate the presentation of the Dynamic Biotechnology and Genome Intellidex Index before charges and costs.

This is involved supplies of 30 U.S. biotechnology and genome organizations. These are organizations that are mainly occupied with the exploration, improvement, assembling, and advertising and conveyance of different biotechnological items, administrations and procedures, and organizations that advantage fundamentally from logical and innovative advances in biotechnology and hereditary designing and research.

In its first-quarter profit telephone call, Puma Biotechnology (PBYI) diminished its direction for financial 2019 net offers of NERLYNX in the US showcase from $255 million to $280 million to $220 million to $240 million. The organization expanded its gauge

Simply put, biotechnology is a technology that is fundamentally based on the biology of living organisms and uses biological processes to develop new products and solutions for the better healthcare of the patients and the society as a whole. Simplest

Perhaps the biggest occasion on the current year's Asian biotechnology schedule united in excess of 1,500 individuals from 25 nations to meet and investigate business openings in Taiwan's rising biotech division. Joined under the gathering subject "Biotech as the Next

Continued here:
Is it advisable for you to Invest in the Invesco Dynamic Biotechnology and Genome ETF (PBE)? - BPhrm Dv

The Department of Agricultural and Environmental Sciences offers the:

and in cooperation with the Department of Biology, the:

Biotechnology applies scientific and engineering principles to living organisms to produce products and services of value to society. Modern biotechnology provides breakthrough products and technologies to:

Students with training in biotechnology enjoyexciting careersthat help feed, fuel and heal the world.

Department Chair:Dr. Samuel Nahashon, (615) 963-5431

Suggested Four-year Plan

17

16

16

16

14

14

14

13

For the BS degree, in addition to the General Education requirements of the university, students in the Biotechnology Concentration take the following courses:

NumberCourse TitleUNIV 1000 OrientationAGSC 1200 Introduction to Plant ScienceAGSC 1410 Introduction to Animal ScienceAGSC 2010 Introduction to AgribusinessAGSC 2200 Fundamentals of Soil ScienceAGSC 2410 Introduction to Poultry ScienceAGSC 3540 Laboratory instrumentationAGSC 4500 Senior ProjectAGSC 4710-4720 SeminarAGSC xxxx Biotechnology and SocietyAGSC xxxx Principals and Methods of Biotechnology IAGSC xxxx Principals and Methods of Biotechnology IIAGSC xxxx Biotechnology in Agricultural ProductionAGSC xxxx Agricultural Bio-securityAGSC xxxx Ethics and Bio-forensics in Ag. BiotechnologyBIOL 4112 BioinformaticsBIOL 1110-1 General Biology I & LabCHEM 2010 Organic Chemistry I & LabBIOL 2110 Cell Biology + LabBIOL 2120, 2121 Genetics + LabCHEM 3410 General Biochemistry I & LabBIOL 3410 Principles General BacteriologBIOL 4110, 4111 Molecular Genetics & Lab

And two credits of electives from the following list:

NumberCourse Title AGSC 3210 Principles of Crop ScienceAGSC 3260 Plant PhysiologyAGSC 3300 Plant PathologyAGSC 3320 Propagation of Horticultural PlantsAGSC 3400 Animal and Plant GeneticsAGSC 3410 Anatomy and Physiology of Domestic AnimalsAGSC 3430 Animal Health and Disease PreventionAGSC 3530 Food MicrobiologyAGSC 4070 Agricultural Special ProblemsAGSC 4310 Plant BreedingAGSC 4410 Dairy Production and ManagementAGSC 4420 Poultry Disease Prevention and SanitationAGSC 4430 Animal NutritionAGSC 4440 Physiology of Reproduction

For additional information:ContactDr. S. Nahashon.

PhD ConcentrationThe Ph.D. concentration in Biotechnology is an interdepartmental degree program that is jointly offered by the Department of Agricultural Sciences and theDepartment of Biological Sciences.

Admission Requirements: Ph.D. Program

Administered by the Department of Biological Sciences. Applicants to the Ph.D. program must submit a completed application form, a personal statement describing interest in the program and professional goals, and three letters of recommendations from persons familiar with the applicant's academic work, especially in biology. The departmental admissions committee will base admission upon these materials and interviews with selected applicants.

Admission requires the applicant have a bachelor's degree from a fully accredited four-year college or university, a minimum score of 1370 calculated from the GPA multiplied by 200 and added to the GRE combined verbal and quantitative scores and a minimum score of 600 on the GRE subject test in biology. Students may also be admitted with subject test scores below 600, but such students must take the departmental diagnostic examination. The admissions committee will evaluate the student's performance on the examination and design a curriculum to eliminate any identified weaknesses. After passing the recommended courses with a grade of "B" or better in each, the student will begin the Ph.D. curriculum.

Programs of Study: Ph.D. Program

The degree candidate must file a program of study after competing nine (9) semester hours of graduate work, but before completing fifteen (15) hours of graduate work. The program lists the courses which will be used to satisfy degree requirements, as well as detailing how other requirements will be met. The student may later change the program of study with the written approval of the Department and the Graduate School.

Admission to Candidacy: Ph.D. Program

The student must apply for admission to candidacy after completing the 24 hour core of required courses (See Degree Requirements below), with an average of "B" (3.00) or better, passing the comprehensive examination, and gaining approval of the dissertation proposal. Students may have a "C" grade in no more than two courses (6 credit hours), neither of which can be a core course. No "D" or "F" grades are acceptable. A student who receives a grade of "C" in excess of six credits must repeat the course and achieve at least a "B".

Degree Requirements: Ph.D. Program

After gaining admission to candidacy, the student must complete an approved curriculum (24 hours minimum of electives set by the student's research advisory committee), enroll in Graduate Seminar (BIOL 7010, 7020), complete a dissertation (24 hours), and successfully defend the dissertation prior to gaining the Ph.D. degree (please refer to Biological Sciences Graduate Student Handbook for specific dissertation requirements). A student entering with a Master's degree may have applicable hours transferred toward the Ph.D. program, as determined by the Advisory Committee. The total number of hours required is 76.

For additional information:ContactDr. S. Nahashon.

Graduate Elective Courses

AGSC 5160 Animal Genetics and BreedingAGSC 5190 Plant BreedingAGSC 7010 Advancements in Agricultural BiotechnologyAGSC 7020 Economic, Regulatory and Ethical Issues in BiotechnologyAGSC 7030 Gene Expression and Regulation and Regulation in Higher PlantsAGSC 7040 Plant Tissue Culture Methods and ApplicationsAGSC 7050 Biotechnology in Animal ReproductionAGSC 7060 Advanced Soil TechnologyAGSC 7070 Molecular Genetic Ecology

The rest is here:
Biotechnology - Tennessee State University

Some of the earliest human uses of biotechnology were the domestication of animals and cultivation of crops for consumption. Other early uses of biotechnology were in specialized breeding programs of food staples by farmers that resulted in crops with high yields that could sustain the larger populations necessary for human society to thrive after the Neolithic Revolution. Biotechnology relating to food and drink also includes leavening yeast for bread and fermentation practices for beer and wine.

In 1928, Alexander Fleming accidentally discovered the mold culture that would eventually became the basis for the antibiotic penicillin. This organism's contribution to human health through its application in the treatment of infections is an example of biotechnology in action. Penicillin and its subsequent drug classes have been in use since 1940.

Modern biotechnology seeks to affect various aspects of human life by creating new types of fuel, improving agricultural practices, and fighting infectious disease. As a result, biotechnology is closely related to the fields of biomedical engineering and bioengineering.

Original post:
What Is Biotechnology Used For? | Reference.com

= By ANGELA OKETCH More by this Author 24minutesago

The chemicals that farmers spray on their crops in form of pesticides to kill pests and prevent diseases have always been a bone of contention, with researchers trying to find safer alternatives. A new variety of rice that fights multiple pathogens with no effect on the yield of the crop, is thus a welcome relief for both farmers and scientists.

The discovery is based on a study of the plants immune system. Plants use receptors on the outside of their cells to identify molecules that signal a microbial invasion, and respond by releasing antimicrobial compounds. Therefore, identifying genes that kickstart this immune response yields disease-resistant plants.

Just like sick humans who are unproductive at work, plants grow poorly and produce unfavourable yields when their immune systems are overloaded. For a long time, scientists have focused on the NPR1 gene from a small, woody plant called Arabidopsis thaliana, to boost the immune systems of rice, wheat, tomatoes and apples.

However, NPR1 is not very useful for agriculture because it has negative effects on plants. To make it useful, researchers needed a better gene that would activate the immune response only when the plant is under attack. Rice with the gene was able to combat rice blast which often causes an estimated 30 per cent loss of rice crop worldwide, every year.

A segment of DNA called the TBF1 cassette acted as a control switch for the plants immune response. When the TBF1 cassette from the Arabidopsis genome was copied and pasted alongside and in front of the NPR1 gene in rice plants, it resulted in a strain of rice that could fend off offending pathogens without causing stunted growth seen in previously engineered crops.

The researchers tested the superiority of engineered rice over regular rice by inoculating crop leaves with the bacterial pathogens that cause rice blight and leaf streak, as well as the fungus responsible for blast disease. Whereas the infections spread on the leaves of wild rice plants, the engineered plants confined the invaders to a small area.

The researchers say this innovation could come in handy in the developing world where farmers with no access to fungicide often lose their entire crop to disease. The study was published in Nature.

open close

Read more here:
Genetic engineering boosts immunity against crop disease - Daily Nation